Bayer (Schweiz) AG and ASPIVIX collaborate to reduce pain in Women’s Health procedures

Bayer (Schweiz) AG and ASPIVIX collaborate to reduce pain in Women’s Health procedures

Epalinges, Switzerland – April 15, 2024 – ASPIVIX announces its partnership with Bayer (Schweiz) AG in Switzerland, aimed at transforming gynecological procedures.
Together, we are introducing Carevix™, a CE-Marked cervical stabilizer designed to minimize pain and bleeding during transcervical procedures, including IUD placement.

This Swiss collaboration combines Bayer (Schweiz) AG’s expertise in contraceptive solutions with ASPIVIX’s commitment to modernizing gynecology. Bayer is a globally recognized leader in women’s health solutions and is one of the world’s top producers of IUDs.

Our shared goal is to offer women a more comfortable and efficient gynecological experience, reducing the cases of pain associated with IUD procedures.

The potential pain during IUD insertion impacts million women worldwide, largely due to the use of the century-old cervical tenaculum in gynecological procedures.
Carevix™, the suction cervical stabilizer, provide an appealing alternative to currently available tenaculum, filling an important unmet need (1) and has demonstrated clinical effectiveness in reducing both pain and bleeding.

ASPIVIX CEO, Mathieu Horras, highlighted the company’s dedication to improving women’s healthcare. “ASPIVIX is excited to enter this partnership with Bayer (Schweiz) AG that truly emphasize the goal of empowering women to select the best contraceptive solution without worrying about potential pain and bleeding. The thorough research and clinical data behind Carevix™ guarantee a notable decrease in pain and bleeding, enhancing the experience of IUD adoption and placement, as well as various other gynecological procedures for millions of women.
Bayer Switzerland Women’s Healthcare lead, Marco Gierten, shares “As a globally trusted brand, Bayer remains committed to advancing solutions that provide significant benefits to patients.

More information:

About Aspivix

Aspivix is a pioneering leader in women’s health, dedicated to modernizing healthcare solutions for women around the world. With a focus on innovation, Aspivix is committed to developing cutting-edge medical devices, such as Carevix™, which aim to transform the gynecological experience by offering safer and less painful solutions that enhance the quality of care and empower women to take control of their health.

About Carevix™

Carevix™ is an innovative, soft-suction cervical device designed as a modern and gentler alternative to a cervical tenaculum when stabilization of the cervix is needed, aiming to significantly reduce trauma associated with pain and bleeding.

Carevix™ has been clinically proven to be atraumatic during transcervical procedures. The First-In-Women highly compelling results from the ADVANCE Women (Atraumatic Device using Vacuum Technology for Cervical Procedures in WOMEN), a randomized controlled trial of Carevix™, used In IUD Procedures against the cervical tenaculum has been published in “Contraception”, the International Reproductive Health Journal in March 2023.

Carevix™ has received FDA-clearance and now CE-Mark approval in 2023 which will allow Carevix™ to be available for commercialization in Europe and the United States of America very soon.

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2023, the Group employed around 100,000 people and had sales of 47.6 billion euros. R&D expenses before special items amounted to 5.8 billion euros.

About Bayer in Switzerland

In Switzerland, Bayer is represented by the three national companies Bayer (Schweiz) AG, Bayer Consumer Care AG and Bayer CropScience Schweiz AG in the cantons of Zurich, Basel and Basel-Landschaft. Bayer employs a total of around 1,450 people in Switzerland. Further information can be found at
Follow Bayer Switzerland on X and LinkedIn

For media inquiries or more information :

Please contact: Ikram Guerd – VP of Global Marketing:


(1) Michal Yaron, Hélène Legardeur, Bastien Barcellini, Farida Akhoundova, Patrice Mathevet, Safety and efficacy of a suction cervical stabilizer for IUD insertion: results from a randomized, controlled study, Contraception, 2023, 110004, ISSN 0010- 7824, Contraception link

More from our blog